Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial. - Mujuru, Hilda Angela; White, Ellen; Kekitiinwa, Adeodata R; Lugemwa, Abbas; Kityo, Cissy; Violari, Avy; Ahimbisibwe, Grace Miriam; Variava, Ebrahim; Archary, Moherndran; Cotton, Mark (Open Forum Infectious Diseases, 2026)